Julianne Gee

Julianne Gee

Auto-generated profile, based on publicly available information

Julianne Gee

National Center for Emerging Zoonotic Infectious Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Vaccine
Verified
Journal Article
Closed access
DGDiane Gubernot
Diane Gubernot
AJAmelia Jazwa
Amelia Jazwa
MNManette Niu
Manette Niu
JBJane Baumblatt
Jane Baumblatt
JGJulianne Gee
Julianne Gee
SBSarah Bennett
Sarah Bennett


2 October 2017 in BMC Public Health
Verified
Journal Article
Open access
PDF file
JVJeffrey J. VanWormer
Jeffrey J. VanWormer
CBCasper Bendixsen
Casper Bendixsen
EVElizabeth R. Vickers
Elizabeth R. Vickers
SSShannon Stokley
Shannon Stokley
MMMichael M. McNeil
Michael M. McNeil
HMHuong Q. McLean
Huong Q. McLean
Human papillomavirus (HPV) vaccine coverage rates remain low. This is believed to reflect parental hesitancy, but few studies have examined how changes in parents’ attitudes impact HPV vaccine uptake. This study examined the association between changes in parents’ vaccine attitudes and HPV vaccine receipt in their adolescent children. A baseline and 1-year follow-up survey of HPV vaccine attitudes was administered to parents of 11–17 year olds who had not completed the HPV vaccine series. Changes in attitudinal scores (barriers, harms, ineffectiveness, and uncertainties) from the Carolina HPV Immunization Attitudes and Beliefs Scale were assessed. Two outcomes were measured (in parents’ adolescent children) over an 18-month period and analyzed using multivariable regression; receipt of next scheduled HPV vaccine dose and 3-dose series completion. There were 221 parents who completed the baseline survey (11% response rate) and 164 with available follow-up data; 60% of their adolescent children received a next HPV vaccine dose and 38% completed the vaccine series at follow-up. Decrease in parents’ uncertainties was a significant predictor of vaccine receipt, with each 1-point reduction in uncertainties score associated with 4.9 higher odds of receipt of the next vaccine dose. Higher baseline harms score was the only significant predictor of lower series completion. Reductions in parents’ uncertainties appeared to result in greater likelihood of their children receiving the HPV vaccine. Only baseline concerns about vaccine harms were associated with lower series completion rate. Education for parents should emphasize the HPV vaccine’s safety profile.

16 April 2024 in Vaccine
Verified
Journal Article
Open access
JGJulianne Gee
Julianne Gee
TSTom T. Shimabukuro
Tom T. Shimabukuro
JSJohn R. Su
John R. Su
DSDavid Shay
David Shay
MRMargaret Ryan
Margaret Ryan
SASteven Anderson
Steven Anderson
The U.S. COVID-19 vaccination program, which commenced in December 2020, has been instrumental in preventing morbidity and mortality from COVID-19 disease. Safety monitoring has been an essential component of the program. The federal government undertook a comprehensive and coordinated approach to implement complementary safety monitoring systems and to communicate findings in a timely and transparent way to healthcare providers, policymakers, and the public. Monitoring involved both well-established and newly developed systems that relied on both spontaneous (passive) and active surveillance methods. Clinical consultation for individual cases of adverse events following vaccination was performed, and monitoring of special populations, such as pregnant persons, was conducted. This report describes the U.S. government's COVID-19 vaccine safety monitoring systems and programs used by the Centers for Disease Control and Prevention, the U.S. Food and Drug Administration, the Department of Defense, the Department of Veterans Affairs, and the Indian Health Service. Using the adverse event of myocarditis following mRNA COVID-19 vaccination as a model, we demonstrate how the multiple, complementary monitoring systems worked to rapidly detect, assess, and verify a vaccine safety signal. In addition, longer-term follow-up was conducted to evaluate the recovery status of myocarditis cases following vaccination. Finally, the process for timely and transparent communication and dissemination of COVID-19 vaccine safety data is described, highlighting the responsiveness and robustness of the U.S. vaccine safety monitoring infrastructure during the national COVID-19 vaccination program.

1 October 2017 in Vaccine
Verified
Journal Article
Closed access
JGJulianne Gee
Julianne Gee
LSLakshmi Sukumaran
Lakshmi Sukumaran
EWEric Weintraub
Eric Weintraub

27 December 2021 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
WAWinston Abara
Winston Abara
JGJulianne Gee
Julianne Gee
MDMark Delorey
Mark Delorey
YTYe Tun
Ye Tun
YMYi Mu
Yi Mu
TSTom Shimabukuro
Tom Shimabukuro
Using meta-analytic methods, we calculated expected rates of 20 potential adverse events of special interest (AESI) that would occur after coronavirus disease 2019 (COVID-19) vaccination within 1-, 7-, and 42-day intervals without causal associations. Based on these expected rates, if 10 000 000 persons are vaccinated, (1) 0.5, 3.7, and 22.5 Guillain-Barre syndrome cases, (2) 0.3, 2.4, and 14.3 myopericarditis cases, (3) and 236.5, 1655.5, and 9932.8 all-cause deaths would occur coincidentally within 1, 7, and 42 days postvaccination, respectively. Expected rates of potential AESI can contextualize events associated temporally with immunization, aid in safety signal detection, guide COVID-19 vaccine health communications, and inform COVID-19 vaccine benefit-risk assessments.